MLL
ABMD

Moody Lynn & Lieberson’s Abiomed Inc ABMD Stock Holding History

Moody Lynn & Lieberson’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,775
Closed -$3.24M – 218
2017
Q4 		$3.24M Buy
+13,775
New +$2.57M 0.35% 61

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Moody Lynn & Lieberson's ABMD Position: Q1 2018 in Review

Moody Lynn & Lieberson sold out of Abiomed Inc (ABMD) in Q1 2018, closing a stake of 13,775 shares — an estimated $3.24M sold.

Moody Lynn & Lieberson first reported a position in ABMD in Q4 2017 and held it in 1 quarter. The position peaked at $3.24M in Q4 2017. 405 funds tracked by Wall St. Rank hold ABMD as of Q1 2018.

  • Moody Lynn & Lieberson reported no remaining Abiomed Inc position as of Q1 2018 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 13,775 Abiomed Inc shares in Q1 2018, an estimated $3.24M.
  • Moody Lynn & Lieberson first reported a position in Abiomed Inc in Q4 2017 and held it in 1 quarter.
  • Moody Lynn & Lieberson's Abiomed Inc position peaked at $3.24M in Q4 2017.
  • 405 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2018.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2018, filed 27 Apr 2018.